Product Name:
HIPK2-BCT
Product Number:
ab-nk272-1
Target Full Name: Homeodomain-interacting protein-serine kinase 2
Target Alias: Homeodomain interacting protein kinase 2; Kinase HIPK2; NBAK1; Nuclear body associated kinase 1; Sialophorin tail associated nuclear serine,threonine kinase; Sialophorin tail associated nuclear serine/threonine kinase; STANK; PRO0593; Q9H2X6; ENSG00000064393
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK272-1
Antibody Target Type: Pan-specific
Protein UniProt: Q9H2X6
Protein SigNET: Q9H2X6
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human HIPK2 sequence peptide Cat. No.: PE-01BDD99
Antibody Immunogen Sequence: HPSQYPAQFAHQTYISASC
Antibody Immunogen Description: Corresponds to amino acid residues H1159 to S1176; Pre-C-terminus
Production Method: Corresponds to amino acid residues H1159 to S1176; Pre-C-terminus
Antibody Modification: Protein kinase pan-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 120-125 kDa.
Related Product 1: HIPK2-BCT blocking peptide
Related Product 2: HIPK1-pY352 phosphosite-specific antibody (Cat. No.: AB-PK654)
Related Product 3: DYRKtide KinSub - DYR peptide substrate
Scientific Background: HIPK2 is a protein-serine/threonine kinase of the CMGC group and DYRK family. It is believed to be involved in inducing apoptosis, through phosphorylation of p53, after genotoxic stress. It interacts with numerous transcription factors (such as p53, AML1(RUNX1), PAX6, c-MYB or NK3) as well as transcriptional regulators (such as CBP, p300, Groucho, CtBP, HMGA1 or Smads). In this way HIPK2 can activate or repress transcription and thereby influence differentiation, development and the DNA damage response. HIPK2 can promote the apoptotic program via p53-dependent and -independent pathways through phosphorylation of p53 at S46 or phosphorylation of the anti-apoptotic co-repressor CtBP at S422 (both actions leading to the transcription of pro-apoptotic target genes). HIPK2 may be an oncoprotein (OP) or a tumour suppressor protein (TSP). HIPK2 is upregulated in some cervical cancers, and down regulated in some thyroid and breast carcinomas. In most cancer systems appears to repress growth and prevent tumourigenesis. In cervical cancer was described to be upregulated but this may represent a compensation of normal cellular machinery.